Fed. Cir.

Endo Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., No. 15-2021 (Fed. Cir. May 16, 2018)

Infringement Invalidity (§ 102/§ 103) Injunction

Court: U.S. Court of Appeals for the Federal Circuit
Case No.: No. 15-2021
Also Docketed: No. 15-2022, No. 15-2023, No. 15-2024, No. 15-2025, No. 15-2026, No. 15-2028, No. 15-2031, No. 15-2033, No. 15-2034, No. 15-2035, No. 15-2041, No. 15-2042, No. 15-2046, No. 15-2047, No. 15-2049, No. 15-2059, No. 15-2060, No. 16-1025, No. 16-1060, No. 16-1117, No. 16-1118 (consolidated; same document)
Decided: May 16, 2018
Judge: Hughes, J.
Document: Nonprecedential Opinion
Length: 25 pages

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Endo Pharmaceuticals Inc. and Grünenthal GmbH sued generic drug manufacturers under the Hatch - Waxman Act in the U.S. District Court for the Southern District of New York, alleging infringement of, among other patents, U.S. Patent Nos. 8,309,122 B2 and 8,329,216 B2. 1 These patents relate to a controlled re- 1 We grant the motions to voluntarily dismiss a p- peal nos. 15-2022, 15-2023, 15-2025, 15-2028, 15-2033, 15- 2034, 15- 2035, 15- 2041, 15 -2042, 15- 2047, 15- 2049, 15- 2059, 15-2060, and 16-1118.

Download Opinion (PDF)

Source: govinfo.gov USCOURTS collection · retrieved July 23, 2026 · Report an error